TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
BCYC

Bicycle Therapeutics Ltd

Healthcare · Biotechnology

3.70$ +0.7% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Bicycle Therapeutics Ltd (BCYC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 15.4% of the shares are freely tradable; institutional investors hold 71.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 71.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 4.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 15.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 8.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 51Mio.

Largest Shareholders

Institutions

Institutions BCYC
Name Stake (%) Shares Change (%) Date
Baker Bros Advisors LP 15.55 10,885,357 +0.0 03/31/2026
FCPM III SERVICES BV 4.96 3,468,430 +0.0 03/31/2026
Armistice Capital, LLC 4.85 3,398,000 +5.0 03/31/2026
Long Focus Capital Management, LLC 4.73 3,310,687 +0.0 06/30/2026
Acadian Asset Management LLC 2.81 1,968,025 +0.0 03/31/2026
Siren, L.L.C. 2.23 1,560,882 -22.5 03/31/2026
GSK PLC 2.19 1,529,561 +0.0 03/31/2026
T. Rowe Price Associates, Inc. 1.47 1,028,243 -12.3 03/31/2026
Renaissance Technologies Corp 1.40 979,300 +72.8 03/31/2026

Funds

Funds BCYC
Name Stake (%) Shares Change (%) Date
Candriam Eqs L Biotech C USD Cap 1.18 825,127 +0.0 02/28/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?